ROBERT E. ENSOR, M.D.; H. RAYMOND PETERS, M.D., F.A.C.P.
Anticoagulant therapy is becoming increasingly important in the prevention and treatment of thrombo-embolic disease. Various investigators, in a search for an "ideal anticoagulant" have expressed preferences for one or the other of several drugs of this type which are available commercially or experimentally. Recently many investigators have favored phenindione (Hedulin) as the "anticoagulant of choice."1
Among the anticoagulant drugs employed in our clinic since 1943 were bishydroxycoumarin (Dicumarol), cyclocumarol (Cumopyran), ethyl biscoumacetate (Tromexan ethyl acetate), phenindione (Hedulin), diphenadione (Dipaxin) and, more recently, phenprocoumon (Marcumar).2 We were greatly impressed with the superiority of phenprocoumon with respect to greater predictability of results
ENSOR RE, PETERS HR. EXPERIENCE WITH THE ANTICOAGULANT, MARCUMAR1. Ann Intern Med. ;47:731–743. doi: 10.7326/0003-4819-47-4-731
Download citation file:
Published: Ann Intern Med. 1957;47(4):731-743.
Cardiology, Gastroenterology/Hepatology, Hospital Medicine.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use